Albireo announces changes to r&d organization

Boston, dec. 09, 2021 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of pat horn, m.d., ph.d., chief medical officer, who will be leaving at the end of the year after almost three and a half years with the company. jan mattsson, ph.d., chief scientific officer and co-founder of albireo, will be taking over as the interim head of r&d, leading research and development of early and late-stage assets and programs. as one of the co-founders of the company with deep experience in drug development and approvals, dr. mattsson is primed to lead the r&d organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.
ALBO Ratings Summary
ALBO Quant Ranking